|
Q3 FY2025
As of Sep 27, 2025
|
Q2 FY2025
As of Jun 28, 2025
|
Q1 FY2025
As of Mar 29, 2025
|
Q4 FY2024
As of Dec 28, 2024
|
Q3 FY2024
As of Sep 28, 2024
|
Q2 FY2024
As of Jun 29, 2024
|
Q1 FY2024
As of Mar 30, 2024
|
Q4 FY2023
As of Dec 30, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jul 1, 2023
|
Q1 FY2023
As of Apr 1, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Oct 1, 2022
|
Q2 FY2022
As of Jul 2, 2022
|
Q1 FY2022
As of Apr 2, 2022
|
Q4 FY2021
As of Jan 1, 2022
|
Q3 FY2021
As of Oct 2, 2021
|
Q2 FY2021
As of Jul 3, 2021
|
Q1 FY2021
As of Apr 3, 2021
|
Q4 FY2020
As of Jan 2, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Short term investments | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Deferred tax assets | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Deferred revenue and customer advances | ||||||||||||||||||||
| Short-term notes payable | ||||||||||||||||||||
| Term loan | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Term loan | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Deferred tax liabilities | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Total long-term liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Preferred stock, 5,000 shares authorized and none outstanding | ||||||||||||||||||||
| Common stock, $0.01 par value, 100,000 shares authorized; 31,825 and 30,629 shares issued and outstanding, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total stockholders' (deficit) equity | ||||||||||||||||||||
| Total liabilities and stockholders' (deficit) equity | ||||||||||||||||||||
| Preferred stock, shares authorized | ||||||||||||||||||||
| Common stock, shares outstanding | ||||||||||||||||||||
| Common stock, shares authorized | ||||||||||||||||||||
| Common stock, par value |
Loading...
